Kezar Life Sciences (NASDAQ:KZR) Shares Up 0.3% – What’s Next?

Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) rose 0.3% on Tuesday . The company traded as high as $6.44 and last traded at $6.32. Approximately 53,233 shares traded hands during mid-day trading, an increase of 27% from the average daily volume of 41,921 shares. The stock had previously closed at $6.30.

Analyst Ratings Changes

Several research firms recently weighed in on KZR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kezar Life Sciences in a report on Monday, December 22nd. Wall Street Zen upgraded shares of Kezar Life Sciences to a “hold” rating in a research report on Saturday, November 22nd. Four analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kezar Life Sciences currently has a consensus rating of “Reduce” and a consensus target price of $6.00.

Kezar Life Sciences Price Performance

The firm has a 50 day moving average of $6.24 and a 200-day moving average of $5.36. The company has a current ratio of 7.07, a quick ratio of 7.06 and a debt-to-equity ratio of 0.02. The company has a market cap of $46.26 million, a P/E ratio of -0.75 and a beta of 0.56.

Institutional Trading of Kezar Life Sciences

A number of large investors have recently made changes to their positions in the stock. Nantahala Capital Management LLC bought a new position in shares of Kezar Life Sciences during the 4th quarter worth $1,741,000. Affinity Asset Advisors LLC purchased a new stake in shares of Kezar Life Sciences during the 4th quarter valued at $1,441,000. BML Capital Management LLC boosted its holdings in Kezar Life Sciences by 55.6% in the second quarter. BML Capital Management LLC now owns 635,183 shares of the company’s stock worth $2,909,000 after acquiring an additional 227,045 shares in the last quarter. Aldebaran Capital LLC purchased a new stake in Kezar Life Sciences during the 4th quarter worth approximately $507,000. Finally, Stonepine Capital Management LLC increased its position in shares of Kezar Life Sciences by 69.9% in the 2nd quarter. Stonepine Capital Management LLC now owns 169,859 shares of the company’s stock valued at $778,000 after acquiring an additional 69,859 shares during the period. 67.90% of the stock is owned by hedge funds and other institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.